← FDA DRUG APPROVALS

FDA ANDA · ANDA062118

CEPHALEXIN

Sponsor: FACTA FARMA

APPLICATION
ANDA062118
TYPE
ANDA
ORIGINAL APPROVAL
1978-03-27
LATEST ACTION
2002-08-27
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

CEPHALEXINDiscontinued
CEPHALEXIN EQ 250MG BASE · CAPSULE · ORAL
CEPHALEXINDiscontinued
CEPHALEXIN EQ 500MG BASE · CAPSULE · ORAL

Approval history

2002-08-27Manufacturing (CMC) · Supplement 35AP
1999-12-23Manufacturing (CMC) · Supplement 34AP
1999-06-01Manufacturing (CMC) · Supplement 33AP
1998-01-28Manufacturing (CMC) · Supplement 32AP
1996-07-12Labeling · Supplement 31AP
1993-10-01Labeling · Supplement 30AP
1992-11-24Labeling · Supplement 27AP
1992-04-13Manufacturing (CMC) · Supplement 25AP
1992-02-07Labeling · Supplement 24AP
1988-10-20Labeling · Supplement 22AP
1978-03-27OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →